It is possible that we depleted some other, non-immunoglobulin component of COVID-19 patient plasma that has the ability to cleave the ACE2 substrate peptide with our 100 kDa size exclusion plus protein A/G treatment procedure. This evidence concerns the gene ACE2 and COVID-19.